Behavioural Brain Research
August 26, 2022
Lakshmi Rajagopal, Mei Huang, Wenqi He et al.
Rapastinel, a positive N-methyl-D-aspartate receptor (NMDAR) modulator with rapid-acting antidepressant properties, rescues memory deficits in rodents. We have previously reported that a single intravenous dose of rapastinel, significantly, but only transiently, prevented and rescued deficits in the novel object recognition (NOR) test, a measure of episodic memory, produced by acute or...
Neuropsychopharmacology
November 2018
Lakshmi Rajagopal, Mei Huang, Eric Michael et al.
GABAergic drugs are of interest for the treatment of anxiety, depression, bipolar disorder, pain, cognitive impairment associated with schizophrenia (CIAS), and other neuropsychiatric disorders. Some evidence suggests that TPA-023, (7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine), a GABAA α2,3 subtype-selective GABAA partial...
Behavioural Brain Research
September 17, 2018
Lakshmi Rajagopal, D Soni, Herbert Y. Meltzer
Pregnenolone sulfate (PregS), an endogenous neurosteroid, which negatively and positively modulates gamma amino butyric acid subunit A (GABAA) and N-methyl D-aspartate (NMDA) receptors (R) respectively, among other potential neuroplastic changes on synaptic processes, has shown some beneficial effects on treating cognitive impairment associated with schizophrenia (CIAS) and negative symptoms....
Behavioural Brain Research
April 16, 2018
Nichole M Neugebauer, Masanori Miyauchi, Tatsuya Sato et al.
Abnormalities in prefrontal cortical and hippocampal GABAergic function are postulated to be major causes of the cognitive impairment associated with schizophrenia (CIAS). There are conflicting views on whether diminished or enhanced GABAergic activity contributes to the deficit in short-term novel object recognition (NOR) in the sub-chronic phencyclidine (scPCP) rodent model of CIAS. This...
Behavioural Brain Research
February 15, 2016
Lakshmi Rajagopal, Jeffrey S Burgdorf, Joseph R Moskal et al.
GLYX-13 (rapastinel), a tetrapeptide (Thr-Pro-Pro-Thr-amide), has been reported to have fast acting antidepressant properties in man based upon its N-methyl-D-aspartate receptor (NMDAR) glycine site functional partial agonism. Ketamine, a non-competitive NMDAR antagonist, also reported to have fast acting antidepressant properties, produces cognitive impairment in rodents and man, whereas...
Neuropharmacology
January 2016
Toshihiro Nomura, Yoshihiro Oyamada, Herman B Fernandes et al.
Repeated administration of non-competitive N-methyl-d-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) to rodents causes long-lasting deficits in cognition and memory, and has effects on behaviors that have been suggested to be models of the cognitive impairment associated with schizophrenia (CIAS). Despite this being a widely studied animal model, little is known about the...
Psychopharmacology
September 2011
Masakuni Horiguchi, Mei Huang, Herbert Y. Meltzer
Subchronic administration to rodents of the N-methyl-D-aspartate non-competitive antagonist, phencyclidine (PCP), impairs novel object recognition (NOR). Atypical antipsychotic drugs (APDs) reverse the effects of subchronic PCP on NOR. The effect of metabotropic glutamate₂/₃ receptor (mGlu₂/₃) agonists upon NOR is unknown. We tested the hypotheses that the mGlu₂/₃ agonist, LY379268, by itself,...
Journal of Pharmacology and Experimental Therapeutics
August 2011
Masakuni Horiguchi, M Huang, Herbert Y. Meltzer
The role of 5-hydroxytryptamine (serotonin) (5-HT)(7) receptor antagonism in the actions of atypical antipsychotic drugs (APDs), e.g., amisulpride, clozapine, and lurasidone, if any, is uncertain. We examined the ability of 5-HT(7) receptor antagonism alone and as a component of amisulpride and lurasidone to reverse deficits in rat novel object recognition (NOR) produced by subchronic treatment...
Psychopharmacology
February 1, 2011
Herbert Y. Meltzer, Masakuni Horiguchi, Bill W Massey
To review the evidence that agents which preferentially affect serotonin (5-HT) attenuate the ability of N-methyl-D-aspartate (NMDA) receptor non-competitive antagonists (NMDA-RA), e.g., phencyclidine (PCP), dizocilpine (MK-801), and ketamine, to stimulate locomotor activity (LA), and to impair novel object recognition (NOR). NMDA-RA-induced increased LA and impairment of NOR are widely used...
Journal of Neurochemistry
March 1, 1990
J. Frank Nash, Herbert Y. Meltzer, Gary A. Gudelsky
Abstract: The effect of the racemic mixture of 3,4‐methy‐lenedioxymethamphetamine (MDMA) on the synthesis of dopamine in the terminals of nigrostriatal and mesolimbic neurons was estimated by measuring the accumulation of 3,4‐dihydroxyphenylalanine (DOPA) in the striatum and nucleus accumbens 30 min following the administration of the l‐aromatic amino acid decarboxylase inhibitor,...
Pharmacology, Biochemistry, and Behavior
August 1, 1989
J F Nash, Herbert Y. Meltzer, Gary A. Gudelsky
40 citations
The repeated administration of 5-methoxy-N,N-dimethyltryptamine (5-MeODMT, 3 mg/kg, twice daily for 14 days) significantly diminished hypothermia and corticosterone secretion induced by an acute challenge with the 5-HT1A agonist 8-OH-DPAT (0.1 mg/kg) when compared to the responses in animals treated chronically with the solvent vehicle. In contrast, the chronic administration of 5-MeODMT did...
Life Sciences
1989
Ramesh Arora, Herbert Y. Meltzer
175 citations
3H-Lysergic acid diethylamide (3H-LSD) binding, a putative measure of 5-HT2 receptor binding, was studied in the blood platelets of 29 depressed patients and 24 normal controls. The Bmax (maximum number of 3H-LSD binding sites) in the blood platelets of depressed patients was significantly greater than that of normal volunteers. This increase in Bmax was due to an increase in female depressed...
Journal of Pharmacology and Experimental Therapeutics
June 1, 1988
Jr Jf Nash, Herbert Y. Meltzer, Gary A. Gudelsky
The racemic mixture of 3,4-methylenedioxymethamphetamine (MDMA), which has been reported to produce selective destruction of serotonergic neurons in the central nervous system, was studied to determine its neuroendocrine and temperature effects and mechanism of action. MDMA elevated serum concentrations of corticosterone in doses ranging from 3 to 20 mg/kg administered i.p. Serum corticosterone...
Pharmacology, Biochemistry, and Behavior
March 1, 1985
Gary A. Gudelsky, J I Koenig, Herbert Y. Meltzer
54 citations
The incidence of "wet dog" shakes elicited by quipazine, the hyperthermic response induced by 5-methoxy-N,N-dimethyltryptamine (5MeODMT) and the hypothermic response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were compared in rats of the Fawn-Hooded (FH) and Sprague-Dawley (SD) strains. The behavioral responses of FH rats to quipazine and 5MeODMT were significantly greater than...
Brain Research
August 8, 1983
Miljana Simonovic, Herbert Y. Meltzer
12 citations
5-Methoxy-N,N-dimethyltryptamine (5-MeODMT), a potent serotonin (5-HT) receptor agonist, exerts a biphasic effect on rat prolactin (PRL) secretion. 5-MeODMT (2.5-10 mg/kg) produces a marked, dose-related but short-lasting (less than 30 min) rise in serum PRL levels. At intervals longer than 30 min, 5-MeODMT (1-15 mg/kg) inhibits the stimulation of PRL secretion by another 5-HT agonist,...
European Journal of Pharmacology
October 15, 1979
Miljana Simonovic, Herbert Y. Meltzer
11 citations
Repeated administration of 5-methoxy-N,N-dimethyltryptamine (5MeODMT, 5 mg/kg, a serotonin agonist, every 3 h for a total of 4 injections) potentiated its prolactin (PRL)-releasing effect and that of two other serotonin agonists, quipazine and N,N-dimethyltryptamine. This pretreatment schedule had no effect on PRL response to anti-dopaminergic drugs. The onset of enhanced PRL response to...
Psychopharmacology
April 11, 1978
Herbert Y. Meltzer, Richard G. Fessler, Miljana Simonovic et al.
24 citations
The hallucinogenic indoleamine drugs N,N-dimethyltryptamine (N,N-DMT), psilocybin, bufotenin, 5-methoxy-N,N-dimethyltryptamine, and N-methyltryptamine, increased rat plasma prolactin (PRL) levels. The increase in plasma PRL produced by N,N-DMT, psilocybin, and bufotenin was inhibited by methysergide, a serotonin receptor blocker. Parachlorophenylalanine (PCPA), an inhibitor of serotonin...
Psychopharmacology
1977
Herbert Y. Meltzer, Richard G. Fessler, Miljana Simonovic et al.
Lysergic acid diethylamide (LSD), 0.05 mg/kg and 0.20 mg/kg, significantly decreased plasma prolactin (PRL) levels in male rats. LSD, 0.20 mg/kg, also inhibits the increase in plasma PRL levels produced by chlorpromazine (CPZ), 5 mg/kg, and alpha-methylparatyrosine (AMPT), 50 mg/kg, both of which interfere with dopaminergic inhibition of PRL secretion. LSD was more potent than methysergide, a...